For example, initial treatment with the third-generation TKI, osimertinib has gained success in improving survival in EGFR-mutated lung cancer, possibly due to the suppression of tumors harboring hidden T790M mutation [57]. The gene discussed is EGFR; the disease is lung carcinoma.